Welcome to our dedicated page for ENANTA PHARMACEUTICALS SEC filings (Ticker: ENTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enanta Pharmaceuticals, Inc. filings document a clinical-stage biotechnology issuer focused on small-molecule therapies for viral infections and immunological diseases. Its Form 8-K disclosures cover financial results, Regulation FD clinical-data materials, research and development updates, material agreements and capital-structure information for common stock traded under ENTA on the Nasdaq Global Select Market.
Proxy and annual meeting filings record governance matters including director elections, advisory executive compensation votes, auditor ratification and amendments to the 2019 Equity Incentive Plan. Other event disclosures also document patent litigation matters, including proceedings involving U.S. Patent No. 11,358,953 and Pfizer's COVID-19 antiviral Paxlovid.
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin filed Amendment No. 2 to a Schedule 13G regarding their holdings in Enanta Pharmaceuticals, Inc. common stock. They report beneficial ownership of 1,444,167 shares, representing 4.97% of the outstanding common stock.
The group has no sole voting or dispositive power and instead holds shared voting and shared dispositive power over all 1,444,167 shares. The percentage is based on 29,078,380 shares outstanding as of May 5, 2026, as reported by Enanta. The filing notes that Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person, and the parties make a joint filing agreement under Rule 13d-1(k).
Farallon Capital Management, L.L.C. and affiliated funds report beneficial ownership of Enanta Pharmaceuticals, Inc. common stock. The group holds 2,418,202 Shares of Enanta’s common stock, representing 8.3% of the outstanding class, with no sole voting or dispositive power and all authority held on a shared basis.
The shares are held directly by a group of investment partnerships referred to as the Farallon Funds, for which Farallon Capital Management, L.L.C. acts as investment manager. A number of managing and senior managing members of the investment manager are also reporting persons, reflecting their shared voting and investment power over these holdings.
Enanta Pharmaceuticals, Inc. reported royalty revenue of $14,359 for the quarter and $50,133 for the nine months ended June 30, 2026, essentially flat year-to-date versus 2025 but lower in the quarter on reduced HCV sales from AbbVie’s MAVYRET/MAVIRET regimen.
Research and development expenses fell to $22,126 for the quarter and $62,428 year-to-date, down sharply as RSV clinical spending declined, while immunology and early discovery investment increased. General and administrative expenses also declined to $9,469 for the quarter and $28,046 year-to-date, reflecting lower stock-based compensation and legal costs.
Net loss narrowed to $19,501 for the quarter and $44,530 for the nine months, compared with $18,255 and $63,189 in 2025. Enanta held $211,493 in cash, cash equivalents and marketable securities and expects this, plus retained HCV royalties, to fund operations into fiscal 2029. The OMERS royalty sale liability stood at $125,073, with an effective imputed interest rate of about 12.8%, and the company added a $75.0 million at-the-market equity facility for additional financial flexibility while advancing RSV and immunology programs.
Enanta Pharmaceuticals, Inc. reported fiscal third quarter 2026 results, reflecting a clinical-stage company investing heavily in virology and immunology while posting continued losses. Revenue for the quarter was $14.4 million, all from royalties on AbbVie’s HCV regimen MAVYRET®/MAVIRET®, down from $18.3 million a year earlier due to lower HCV sales.
Research and development expenses fell to $22.1 million and general and administrative expenses to $9.5 million, helping limit the quarterly net loss to $19.5 million, or $0.67 per diluted share. Cash, cash equivalents and marketable securities totaled $211.5 million at June 30, 2026, and the company expects this, along with retained royalties, to fund operations into fiscal 2029. Enanta highlighted progress in its RSV program, including dosing initiation in the Phase 2b pediatric LOTUS trial of zelicapavir and preparation for RESOLVE, a registrational Phase 2b/3 trial in high-risk adults, with topline data from both expected in 2027. It also advanced immunology candidates EDP-978 (KIT inhibitor), EPS-3903 (STAT6 inhibitor) and MRGPRX2-targeting compounds, and noted European Commission approval of MAVIRET for acute HCV, which supports ongoing royalty revenue.
ENANTA PHARMACEUTICALS INC Chief Medical Officer Scott T. Rottinghaus reported a Code F transaction involving company common stock. On 2026-08-08, 1,467 shares of common stock were forfeited at a reference value of $13.34 per share to cover withholding taxes arising from the settlement of a portion of a restricted stock unit award originally granted on August 8, 2022. Following this tax-withholding disposition, Rottinghaus directly holds 23,787 shares of ENANTA common stock.
Enanta Pharmaceuticals entered an Open Market Sale Agreement with Jefferies LLC that allows it to sell up to $75,000,000 of common stock from time to time through an at-the-market program. Shares will be issued under Enanta’s effective Form S-3 shelf registration and a July 2, 2026 prospectus supplement.
Jefferies will act as sales agent and use commercially reasonable efforts to place shares on Nasdaq or other markets, earning a commission of up to 3.0% of the gross sales price per share. Enanta is not obligated to sell any shares, and the arrangement can be terminated in accordance with the agreement’s terms.
Enanta Pharmaceuticals intends to offer and sell up to $75,000,000 of its common stock through an Open Market Sale (sales agreement) with Jefferies LLC as sales agent under an at-the-market offering structure. The sales agreement permits sales from time to time through Jefferies, which may receive commissions up to 3.0% of aggregate gross proceeds. The prospectus supplement uses an assumed offering price of $14.77 per share (the last reported sale price on July 1, 2026) to illustrate an aggregate issuance of 5,077,860 shares and presents illustrative dilution and as-adjusted net tangible book value. Shares outstanding are shown as 29,061,152 as of March 31, 2026. Sales may occur at varying prices and quantities; Jefferies is not required to sell any specific amount and will act using commercially reasonable efforts on mutually agreed terms.
Enanta Pharmaceuticals, Inc. reported that the United States Court of Appeals for the Federal Circuit has affirmed a prior summary judgment ruling in its patent case against Pfizer Inc. The Federal Circuit ruled that the claims of Enanta’s U.S. Patent No. 11,358,953, related to Pfizer’s COVID-19 antiviral Paxlovid, are invalid, effectively upholding the December 2024 decision from the U.S. District Court for the District of Massachusetts.
Enanta Pharmaceuticals is advancing its RSV antiviral zelicapavir into a single registrational Phase 2b/3 trial in high-risk adult outpatients after a successful End-of-Phase 2 FDA meeting. The Phase 2b portion will enroll at least 200 patients, with approximately 660 more in Phase 3, and topline Phase 2b data expected in 2027.
The company also plans a Phase 2b pediatric trial in children 28 days to 36 months old, starting in the third quarter of 2026, with topline data also expected in 2027. Earlier Phase 2 data showed clinically meaningful improvements, including a 6.7-day faster symptom resolution and lower RSV-related hospitalizations in high-risk adults, and antiviral and symptom benefits in children.
Zelicapavir, an RSV N-protein inhibitor with FDA Fast Track designation, has been well tolerated in more than 700 subjects. Enanta estimates an oral RSV antiviral for children and high-risk adults represents a global opportunity of over $2 billion, with a potential U.S. addressable population greater than 3 million patients.
Enanta Pharmaceuticals reported royalty-based revenue of $17.2 million for the three months ended March 31, 2026, up from $14.9 million a year earlier, driven by higher MAVYRET/MAVIRET sales at AbbVie. Net loss narrowed to $13.1 million from $22.6 million as research and development spending fell to $19.4 million and general and administrative costs declined to $9.6 million.
For the six-month period, revenue reached $35.8 million and net loss was $25.0 million. The company ended the quarter with $227.0 million in cash, cash equivalents and marketable securities and expects this, plus its retained share of HCV royalties, to fund operations into fiscal 2029. Enanta continues to advance wholly owned RSV and immunology programs, including Phase 2 RSV candidate zelicapavir and a new Phase 1 KIT inhibitor, while carrying a royalty sale liability of $128.8 million related to its OMERS transaction.